焦虑严重程度与按Lyon 2.0分类的胃食管反流病表型中质子泵抑制剂无应答的关联
本研究分析204例接受治疗外pH阻抗监测和汉密尔顿焦虑量表评估的患者,按Lyon 2.0标准分类。质子泵抑制剂应答率从确定性胃食管反流病(70.2%)逐渐降至无胃食管反流病(30.8%)(P < .001)。焦虑与无应答显著相关,尤其在无胃食管反流病患者中(OR 1.22,P < .001),但在确定性胃食管反流病中不显著。
要点
- 质子泵抑制剂应答率随Lyon 2.0分类从确定性胃食管反流病到无胃食管反流病逐步下降。
- 无应答者焦虑评分显著高于应答者(20.9 ± 9.8 vs 13.4 ± 6.3;P < .001)。
- 焦虑严重程度增加与应答率显著降低相关(轻度59.0%、中度20.5%、重度7.7%;P < .001)。
核心结论
- 焦虑与质子泵抑制剂难治显著相关,尤其在无胃食管反流病患者中。
- 将焦虑评估整合入诊断框架可能有助于优化治疗策略并减少不适当的质子泵抑制剂使用,但需前瞻性研究确认。
研究设计与样本
- 分析204例连续接受治疗外pH阻抗监测和汉密尔顿焦虑量表评估的患者,按Lyon 2.0标准分类。
- 采用多变量逻辑回归和受试者工作特征分析。
主要发现
- 质子泵抑制剂应答率从确定性胃食管反流病(70.2%)降至不确定胃食管反流病伴支持证据(53.3%)、不确定胃食管反流病不伴支持证据(31.6%)和无胃食管反流病(30.8%)(P < .001)。
- 无应答者焦虑评分显著高于应答者(20.9 ± 9.8 vs 13.4 ± 6.3;P < .001)。
- 焦虑与质子泵抑制剂无应答在不确定胃食管反流病伴支持证据患者中显著相关(每增加1分汉密尔顿焦虑量表评分OR 1.14;P = .004),在无胃食管反流病患者中亦显著(OR 1.22;P < .001),但在确定性胃食管反流病患者中不显著。
- 焦虑严重程度增加与应答率显著降低相关(轻度59.0%、中度20.5%、重度7.7%;P < .001)。
- 汉密尔顿焦虑量表对质子泵抑制剂无应答具有良好区分度(总体曲线下面积0.73),在无胃食管反流病患者中表现最佳(曲线下面积0.78)。
临床怎么用
- 在胃食管反流病诊断框架中考虑纳入焦虑评估,尤其对质子泵抑制剂无应答且无胃食管反流病的患者。
- 焦虑评估可能有助于优化治疗策略并减少不适当的质子泵抑制剂使用。
局限性
- 焦虑在管理治疗策略中的作用需前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Persistent symptoms, despite proton pump inhibitor therapy, are common in patients with gastroesophageal reflux disease. The Lyon Consensus 2.0 provides an objective diagnostic framework, but factors associated with proton pump inhibitor nonresponse across gastroesophageal reflux disease phenotypes remain incompletely defined. The aim of this study was to assess the association between anxiety severity and proton pump inhibitor response across gastroesophageal reflux disease phenotypes defined by the Lyon 2.0 classification. METHODS: We analyzed 204 consecutive patients undergoing off-therapy pH impedance monitoring and anxiety assessment using the Hamilton Anxiety Rating Scale. Patients were classified according to Lyon 2.0 criteria. Multivariable logistic regression and receiver operating characteristic analyses were performed. RESULTS: Proton pump inhibitor response rates progressively declined from conclusive gastroesophageal reflux disease (70.2%) to inconclusive gastroesophageal reflux disease with supportive evidence (53.3%), inconclusive gastroesophageal reflux disease without supportive evidence (31.6%), and no gastroesophageal reflux disease (30.8%) (P < .001). Nonresponders showed significantly higher anxiety scores than responders (20.9 ± 9.8 vs 13.4 ± 6.3; P < .001). Anxiety was significantly associated with proton pump inhibitor nonresponse in patients with inconclusive gastroesophageal reflux disease with supportive evidence (odds ratio, 1.14 per 1-point Hamilton Anxiety Rating Scale increase; P = .004) and in patients with no gastroesophageal reflux disease (odds ratio, 1.22; P < .001), but not in patients with conclusive gastroesophageal reflux disease. Increasing anxiety severity was associated with a marked reduction in response rates (59.0% mild, 20.5% moderate, 7.7% severe; P < .001). The Hamilton Anxiety Rating Scale demonstrated good discrimination for proton pump inhibitor nonresponse (area under the curve = 0.73 overall), with highest performance observed in patients with no gastroesophageal reflux disease (area under the curve = 0.78). CONCLUSIONS: Anxiety is significantly associated with proton pump inhibitor refractoriness, particularly in patients with no gastroesophageal reflux disease. Integrating anxiety evaluation into the diagnostic framework may contribute in both optimizing therapeutic strategies and reducing inappropriate proton pump inhibitor use, although its role in managing treatment strategies requires confirmation in prospective studies.
引用
- Ribolsi M, Marchetti L, Galdi L, et al. Anxiety Severity and Proton Pump Inhibitor Nonresponse Association Across Gastroesophageal Reflux Disease Phenotypes Defined by the Lyon 2.0 Classification. Clin Gastroenterol Hepatol. 2026. PMID: 42264337. doi:10.1016/j.cgh.2026.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。